Evommune, Inc. EVMN R2K
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Trading 26.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | EVMN Evommune, Inc. R2K | 23.23 | - | $836.71M | - | -39.16% | -44.95% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 3.00M | 10.00M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 16.52M | 21.45M | - | 23.33M | 29.72M | 23.95M |
| Operating Income | -16.52M | -21.45M | -15.03M | -13.33M | -29.72M | -23.95M |
| EBITDA | -16.19M | -21.09M | - | -13.02M | -29.39M | -23.61M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | -15.92M | -20.73M | - | -12.47M | -28.27M | -21.67M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -15.92M | -20.73M | -14.56M | -12.47M | -28.27M | -21.67M |
| Diluted EPS | -0.99 | - | -9.48 | -0.41 | -1.43 | -0.64 |
| R&D Expense | 13.29M | - | 14.36M | 19.64M | - | 17.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | - | 13.00M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | - | 94.07M |
| Operating Income | - | -81.07M |
| EBITDA | - | -79.68M |
| Interest Expense | - | - |
| Pretax Income | - | -68.87M |
| Tax Provision | - | - |
| Net Income | - | -68.87M |
| Diluted EPS | -4.27 | - |
| R&D Expense | 64.24M | 74.04M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | - | 224.95M |
| Current Assets | - | - | 153.48M |
| Cash & Equivalents | - | - | 44.06M |
| Inventory | - | - | - |
| Receivables | - | - | - |
| Total Liabilities | - | - | 19.38M |
| Current Liabilities | - | - | 17.91M |
| Long Term Debt | - | - | - |
| Total Debt | - | 1.02M | 1.71M |
| Total Equity | -77.71M | - | 205.57M |
| Shares Outstanding | - | - | 31.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -58.20M | -76.44M |
| Investing Cash Flow | -3.99M | -115.31M |
| Financing Cash Flow | 49.42M | 220.76M |
| Capital Expenditure | -88.00K | -235.00K |
| Free Cash Flow | -58.28M | -76.68M |
| Net Change in Cash | - | 29.02M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | -623.6% |
| Net Margin % | - | -529.8% |
| ROE % | - | -33.5% |
| ROCE % | - | -39.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Eqt Fund Management S.a R.l. | 13.69% | 4.93M | $114.52M |
| 2 | RA Capital Management, L.P. | 9.70% | 3.49M | $81.18M |
| 3 | Pivotal bioVenture Partners Investment Advisor, LLC | 5.35% | 1.93M | $44.76M |
| 4 | Andera Partners | 5.27% | 1.90M | $44.08M |
| 5 | RTW Investments LP | 4.17% | 1.50M | $34.90M |
| 6 | JPMORGAN CHASE & CO | 4.05% | 1.46M | $33.90M |
| 7 | MPM Bioimpact LLC | 4.04% | 1.46M | $33.82M |
| 8 | Nan Fung Group Holdings Limited | 4.00% | 1.44M | $33.48M |
| 9 | SymBiosis Capital Partners, LLC | 3.56% | 1.28M | $29.75M |
| 10 | Eventide Asset Management LLC | 3.36% | 1.21M | $28.09M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EVMN